NAVA.OL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 1167 min ago

@ Kr.33.40

Wydano: 6 geg. 2024 @ 15:27

Zwrot: 0.60%

Poprzedni sygnał: geg. 6 - 13:23

Poprzedni sygnał: Sprzedaż

Zwrot: 0.00 %

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 15:40):
Our systems believe the stock currently is overvalued by 0.03% compare to its pairs and should correct downwards.

Stats
Dzisiejszy wolumen	31 429.00
Średni wolumen	86 368.00
Kapitalizacja rynkowa	568.31M
EPS	Kr.0.390 ( 2023-11-01 )
Następna data zysków	( Kr.0 ) 2024-05-31
Last Dividend	Kr.0.998 ( 2010-04-13 )
Next Dividend	Kr.0 ( N/A )
P/E	28.47
ATR14	Kr.1.100 (3.27%)

Korelacja (AI algo v.1.1b): Overvalued: -0.03% Kr.33.59 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: 0.00 (neutral)

Krótki: 0.00 (neutral)

Signal:(66) Neutral

Navamedic ASA Korelacja

10 Najbardziej pozytywne korelacje
NORSE.OL	0.895
SMOP.OL	0.871
NTEL.OL	0.871
TOM.OL	0.868
ENDUR.OL	0.839
XXL.OL	0.838
KIT.OL	0.832
SNI.OL	0.826
BORR.OL	0.815
AYFIE.OL	0.813

10 Najbardziej negatywne korelacje
AKBM.OL	-0.895
ODL.OL	-0.895
SCATC.OL	-0.893
SBX.OL	-0.87
OKEA.OL	-0.858
VOLUE.OL	-0.857
PHO.OL	-0.854
FRO.OL	-0.852
TRVX.OL	-0.846
XPLRA.OL	-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Navamedic ASA Korelacja - Waluta/Towar

0.00
( neutral )

Navamedic ASA Finanse

Annual	2023
Przychody:	Kr.512.00M
Zysk brutto:	Kr.123.46M (24.11 %)
EPS:	Kr.0.190

FY	2023
Przychody:	Kr.512.00M
Zysk brutto:	Kr.123.46M (24.11 %)
EPS:	Kr.0.190

FY	2022
Przychody:	Kr.382.14M
Zysk brutto:	Kr.163.52M (42.79 %)
EPS:	Kr.1.750

FY	2021
Przychody:	Kr.278.44M
Zysk brutto:	Kr.111.74M (40.13 %)
EPS:	Kr.0.00774

Financial Reports:

No articles found.

Navamedic ASA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
Kr.0 (N/A)	Kr.0 (N/A)	Kr.0 (N/A)	Kr.0 (N/A)	Kr.0 (N/A)	Kr.0 (N/A)	Kr.0 (N/A)	Kr.0 (N/A)	Kr.0 (N/A)	Kr.0 (N/A)

Navamedic ASA Dividend Information - No Dividend Player

Dividend Sustainability Score: 2.56 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	Kr.0.998	2010-04-13
Last Dividend	Kr.0.998	2010-04-13
Next Dividend	Kr.0	N/A
Payout Date	2010-04-27
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	Kr.0.998	--
Avg. Dividend % Per Year	0.00%	--
Score	0.07	--
Div. Sustainability Score	2.56
Div.Growth Potential Score	0
Div. Directional Score	0.187	--

Next Divdend (Est)
(2024-05-07)

Kr.0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.07

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2010	Kr.0.998	17.80%
2011	Kr.0	0.00%
2012	Kr.0	0.00%
2013	Kr.0	0.00%
2014	Kr.0	0.00%
2015	Kr.0	0.00%
2016	Kr.0	0.00%
2017	Kr.0	0.00%
2018	Kr.0	0.00%
2019	Kr.0	0.00%
2020	Kr.0	0.00%
2021	Kr.0	0.00%
2022	Kr.0	0.00%
2023	Kr.0	0.00%
2024	Kr.0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
ALNG.OL	Dividend King	2023-11-27	Quarterly	2	6.60%	7.04
OKEA.OL	Dividend Knight	2023-12-01	Quarterly	3	5.65%	6.86
SALM.OL	Dividend Knight	2023-06-09	Annually	17	2.80%	4.97
BWLPG.OL	Dividend Knight	2023-11-17	Quarterly	11	1.68%	4.46
BWO.OL	Dividend Knight	2023-11-20	Quarterly	14	0.87%	3.96
ATEA.OL	Dividend Knight	2023-11-20	Annually	16	2.97%	3.45
HAFNI.OL	Dividend Knight	2023-11-23	Semi-Annually	5	1.18%	3.31
AKER.OL	Dividend Knight	2023-11-07	Semi-Annually	20	2.99%	3.13
AUSS.OL	Dividend Knight	2023-05-26	Annually	17	3.23%	2.93
GSF.OL	Dividend Knight	2023-06-28	Annually	15	3.81%	2.67

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0224	1.500	-0.448	-0.672	[0 - 0.5]
returnOnAssetsTTM	-0.0213	1.200	-0.711	-0.853	[0 - 0.3]
returnOnEquityTTM	-0.0521	1.500	-1.690	-2.54	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.378	0.800	8.11	6.49	[1 - 3]
quickRatioTTM	0.439	0.800	-2.12	-1.698	[0.8 - 2.5]
cashRatioTTM	0.146	1.500	-0.298	-0.447	[0.2 - 2]
debtRatioTTM	0.275	-1.500	5.41	-8.12	[0 - 0.6]
interestCoverageTTM	1.577	1.000	-0.527	-0.527	[3 - 30]
operatingCashFlowPerShareTTM	-0.622	2.00	-0.207	-0.415	[0 - 30]
freeCashFlowPerShareTTM	-0.740	2.00	-0.370	-0.740	[0 - 20]
debtEquityRatioTTM	0.653	-1.500	7.39	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.243	1.000	9.29	9.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0227	1.000	-1.546	-1.546	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.0727	1.000	-1.515	-1.515	[0.2 - 2]
assetTurnoverTTM	0.952	0.800	6.99	5.59	[0.5 - 2]
Total Score				2.56

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-50.70	1.000	-5.22	0	[1 - 100]
returnOnEquityTTM	-0.0521	2.50	-1.087	-2.54	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.740	2.00	-0.247	-0.740	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.622	2.00	-0.207	-0.415	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.822	1.500	-8.82	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0210	1.000	-3.03	0	[0.1 - 0.5]
Total Score				-2.19

Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.